SEC Form 4 · accession 0001213900-26-082804
MoonLake Immunotherapeutics · MLTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristian Reich
Officer — Chief Scientific Officer
Period of report
Jul 27, 2026
Accepted (ET)
Jul 29, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001821586
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per shareF2 | Jul 27, 2026 | S | 1,100 | $20.00 | D | 2,711,198 | I | See footnote. |
| Class A ordinary shares, par value $0.0001 per share | holding | — | — | — | 35,389 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
- F2Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.